Insider
Penumbra IncPEN

Penumbra reports higher revenue, lower net income

Penumbra, Inc. reported its third-quarter results on October 29, 2026, recording a 7.8% decline in net income and an 8.5% drop in earnings per share (EPS) compared to the same period last year. Despite overall revenue growth, these figures indicate a shift in business profitability for the quarter.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
An operating room with a surgical table, overhead lights, and medical equipment
Photo by Marcel Scholte on Unsplash
$410.1 million
Quarterly revenue
$42.3 million
Net income
$1.07
Diluted EPS

Key points

  • For the three months ended September 30, 2026, the company posted revenue of $410.1 million, a 15.6% increase from the prior year.
  • The company continues to operate under its merger agreement with Boston Scientific Corporation, announced January 14, 2026.

Third-quarter financial results

For the three months ended September 30, 2026, the company posted revenue of $410.1 million, a 15.6% increase from the prior year. Gross profit rose 16.6% to $280.3 million, and operating income was $50.7 million, up 3.9%. However, net income fell to $42.3 million, and diluted earnings per share (EPS) declined to $1.07.

Quarter vs the same quarter a year earlier

Jul–Sep 2025Jul–Sep 2026Revenue+15.6%$355M$410MGross profit+16.6%$240M$280MOperating income+3.9%$48.8M$50.7MNet income-7.8%$45.9M$42.3M
Data from the original sources listed alongside.

Merger agreement status

The company continues to operate under its merger agreement with Boston Scientific Corporation, announced January 14, 2026. Under the terms, Penumbra shares are valued at $374, with shareholders entitled to receive cash or Boston Scientific stock in an approximately 73% to 27% split.

Penumbra manufactures most of its products in Alameda and Roseville, California. The company relies on individual purchase orders rather than long-term commitments. International sales accounted for 20.9% of quarterly revenue, and the company does not use hedging to mitigate currency risks.

What to watch

A key issue for shareholders remains the closing date of the merger with Boston Scientific Corporation, which is currently pending, according to regulatory filings.

Original sources

  1. financial data (XBRL)October 29, 2026SHA-256 of our archived copy e0e14b19579d…
  2. 10-Q filing, October 29, 2026October 29, 2026SHA-256 of our archived copy a69d1f770948…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards